<DOC>
	<DOCNO>NCT00295997</DOCNO>
	<brief_summary>RATIONALE : Giving low dos chemotherapy donor stem cell transplant use stem cell closely match patient 's stem cell , help stop growth cancer cell . It also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune system help destroy remain cancer cell ( graft-versus-tumor effect ) . Giving infusion donor 's T cell ( donor lymphocyte infusion ) transplant may help increase effect . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving antithymocyte globulin transplant cyclosporine mycophenolate mofetil transplant may stop happen . PURPOSE : This clinical trial study well donor stem cell transplant work treat patient hematologic cancer , metastatic kidney cancer , aplastic anemia .</brief_summary>
	<brief_title>Donor Stem Cell Transplant Treating Patients With Hematologic Cancer , Metastatic Kidney Cancer , Aplastic Anemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine treatment-related mortality ( TRM ) rate 100 day patient hematologic malignancy , metastatic renal cell carcinoma , aplastic anemia undergo nonmyeloablative allogeneic stem cell transplantation use match unrelated donor . Secondary - Determine TRM 12 month patient treat regimen . - Determine 6-month engraftment rate patient treat regimen . - Determine 1-year overall survival patient treat regimen . OUTLINE : - Nonmyeloablative preparative regimen : Patients receive fludarabine IV 30 minute day -7 -3 , busulfan* IV 6 hour day -4 -3 , anti-thymocyte globulin IV 6-10 hour day -4 -1 . NOTE : *Patients aplastic anemia receive cyclophosphamide IV 2 hour day -6 -3 instead busulfan . - Allogeneic stem cell reinfusion : Patients undergo allogeneic bone marrow peripheral blood stem cell transplantation day 0 . Patients receive filgrastim ( G-CSF ) subcutaneously daily begin day 7 continue blood count recover . - Graft-vs-host disease ( GVHD ) prophylaxis : Patients receive tacrolimus orally twice daily IV continuously begin day -2 continue approximately 6-12 month transplantation . Patients also receive mycophenolate mofetil orally IV twice daily day 0 60 methotrexate IV day 1 , 3 , 6 , 11** . NOTE : **Patients aplastic anemia receive methotrexate IV day 1 , 3 , 6 ( day 11 ) . - Donor lymphocyte infusion ( DLI ) : After day 180 , patient evidence active GVHD may receive DLI . A second DLI may infuse &gt; 8 week first absence disease response GVHD . After completion study treatment , patient follow periodically least 2 year . PROJECTED ACCRUAL : A total 35 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : Aplastic anemia responsive immunosuppressive therapy Metastatic renal cell carcinoma Hematologic malignancy , include follow : Acute myeloid leukemia ( AML ) * curable chemotherapy meeting follow criterion : AML highrisk cytogenetic abnormality ( e.g. , 7 , 7q , 5 , 5q , complex , Philadelphia chromosomepositive [ Ph+ ] ) AML evolve prior myelodysplasia AML secondary prior chemotherapy Failed achieve remission In second subsequent remission NOTE : *Marrow blast &lt; 10 % achieve chemotherapy Myelodysplasia* follow highrisk feature : Adverse cytogenetics ( 7 , 7q , 5 , 5q , complex ) Excess blast Prior conversion AML Severe cytopenias absolute neutrophil count &lt; 500/mm^3 platelet count &lt; 20,000/mm^3 NOTE : *Marrow blast &lt; 10 % achieve chemotherapy Acute lymphoblastic leukemia ( ALL ) * curable chemotherapy meeting follow criterion : Highrisk cytogenetics ( Ph+ , 11q23 abnormality , monosomy 7 ) More 1 induction course require achieve remission Failed enter remission In second subsequent remission NOTE : *Marrow blast &lt; 10 % Chronic lymphocytic leukemia ( CLL ) highrisk feature , include follow : Refractory initial subsequent therapy Progression initial response therapy Prolymphocytic morphology Follicular lymphoma follow highrisk feature : Refractory initial subsequent therapy Progression response initial therapy Has â‰¥ 3 International Prognostic Index ( IPI ) risk factor Multiple myeloma Stage IIIII disease confirm diagnosis initial progression Other lymphoma fail respond primary therapy , progress , recur prior therapy , include follow : Diffuse large cell lymphoma Mantle cell lymphoma Hodgkin 's lymphoma Myeloproliferative disease evidence disease acceleration , include follow : Myelofibrosis Polycythemia vera Essential thrombocythemia Chronic myeloid leukemia ( CML ) fail control imatinib mesylate Disease must stable respond therapy No rapid progression malignant disease Expected time disease progression &gt; 12 week Not eligible autologous stem cell transplantation Matched unrelated donor available 9/10 HLA match , include HLAA , B , C , DR , DQ PATIENT CHARACTERISTICS : Creatinine &lt; 2.0 mg/dL Creatinine clearance &gt; 40 mL/min Bilirubin &lt; 3 mg/dL Elevated total bilirubin due Gilbert 's disease allow direct bilirubin normal AST &lt; 4 time upper limit normal Hepatitis C B allow provide bilirubin AST normal Cardiac ejection fraction &gt; 30 % DLCO &gt; 40 % predict Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No uncontrolled active infection require ongoing antibiotic treatment No poor performance status No poor organ function PRIOR CONCURRENT THERAPY : See Disease Characteristics Prior stem cell bone marrow transplantation allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>juvenile myelomonocytic leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>